2 weeks Ago By ABMN Staff
Wells Fargo & Company MN boosted its position in Qiagen ( NYSE:QGEN – Free Report ) by 31.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 66,779 shares of the company’s stock after acquiring an additional 16,106 shares during the period.
Wells Fargo & Company MN’s holdings in Qiagen were worth $2,974,000 at the end of the most recent reporting period. A number of other hedge funds have also recently modified their holdings of QGEN. Barclays PLC grew its stake in shares of Qiagen by 170.
6% in the third quarter. Barclays PLC now owns 1,849,004 shares of the company’s stock worth $84,259,000 after purchasing an additional 1,165,594 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in Qiagen in the 3rd quarter worth approximately $53,000.
Tidal Investments LLC bought a new stake in shares of Qiagen in the 3rd quarter worth approximately $490,000. JPMorgan Chase & Co. increased its stake in shares of Qiagen by 36.
0% during the third quarter. JPMorgan Chase & Co. now owns 1,604,034 shares of the company’s stock valued at $73,096,000 after buying an additional 424,937 shares during the period.
Finally, GAMMA Investing LLC raised its holdings in shares of Qiagen by 170.1% during the fourth quarter. GAMMA Investing LLC now owns 1,518 shares of the company’s stock valued at $68,000 after acquiring an additional 956 shares in the last quarter.
Hedge funds and other institutional investors own 70.00% of the company’s stock. Analyst Upgrades and Downgrades A number of research analysts have issued reports on the stock.
Redburn Atlantic downgraded shares of Qiagen from a “buy” rating to a “neutral” rating in a research report on Friday, April 4th. Morgan Stanley reissued an “equal weight” rating and issued a $46.67 price target (down from $48.
61) on shares of Qiagen in a research note on Monday, January 6th. UBS Group cut their price objective on Qiagen from $50.00 to $48.
00 and set a “neutral” rating on the stock in a research report on Friday, February 7th. Baird R W lowered Qiagen from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 19th. Finally, Robert W.
Baird raised their target price on Qiagen from $42.00 to $43.00 and gave the company a “neutral” rating in a research note on Monday.
Eight equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $47.
83. Qiagen Stock Performance Shares of QGEN opened at $42.32 on Thursday.
The company has a quick ratio of 3.09, a current ratio of 3.61 and a debt-to-equity ratio of 0.
38. The stock has a market cap of $9.41 billion, a P/E ratio of 117.
84, a P/E/G ratio of 2.39 and a beta of 0.62.
The business’s 50 day moving average price is $39.85 and its 200-day moving average price is $41.71.
Qiagen has a 52 week low of $37.63 and a 52 week high of $49.30.
Qiagen ( NYSE:QGEN – Get Free Report ) last released its earnings results on Wednesday, February 5th. The company reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.
60 by $0.01. Qiagen had a return on equity of 13.
92% and a net margin of 4.23%. Equities research analysts anticipate that Qiagen will post 2.
26 earnings per share for the current fiscal year. Qiagen Profile ( Free Report ) QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.
See Also Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen ( NYSE:QGEN – Free Report ). Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.
com's FREE daily email newsletter ..
